Ascentage Pharma’s Phase III study of Olverembatinib cleared by FDA
The US FDA's clearance of the trial marks the first global registrational Phase III trial for olverembatinib in patients with CP-CML to be conducted.
The US FDA's clearance of the trial marks the first global registrational Phase III trial for olverembatinib in patients with CP-CML to be conducted.
Yescarta is First CAR T-cell therapy to receive NCCN treatment guideline category 1 recommendation --
Colorectal Cancer Screening is now translated into multiple languages to help people worldwide understand why, when and how to screen for colorectal cancer
The revolutionary genetic test helps screen common genes associated with hereditary breast and ovarian cancer in women above 18 years of age
Fyarro added to NCCN guidelines as the only preferred mTOR inhibitor to treat malignant PEComa
Subscribe To Our Newsletter & Stay Updated